Livmarli benefits seen across PFIC types, trial data show
Treatment with Livmarli (maralixibat) leads to significant clinical benefits for people with progressive familial intrahepatic cholestasis (PFIC) across a wide range of disease…
Lindsey Shapiro, PhD, Science Writer — 
Articles by Lindsey Shapiro
Chronic hepatitis B undertreated globally, real-world study finds
Global rates for evaluating chronic hepatitis B and starting appropriate treatment are lower than they should be, especially among women and Asian minorities living…
Bylvay eases itch, signs of liver damage in Alagille, trial data show
Daily treatment with Bylvay (odevixibat) safely and effectively eases itching and lowers blood bile acid levels, a sign of liver damage, in children and adolescents…
Hepatitis Awareness Month promotes screening, vaccination
Throughout May, the U.S. Centers for Disease Control and Prevention (CDC) will work with public health partners to raise awareness of viral hepatitis…
Gilead awards $4M funding to hepatitis B, C, D elimination projects
Gilead Sciences has awarded $4 million in funding via its ALL4LIVER grant program to organizations worldwide whose community-based efforts will help the World Health…
FXR314 well tolerated, lowers liver fat, Phase 2 MASH trial shows
FXR314, an investigational oral therapy, safely and effectively reduced liver fat content in adults with a severe form of fatty liver disease called metabolic…
Madrigal CEO: Rezdiffra OK for NASH a ‘watershed moment’
The approval of Rezdiffra (resmetirom) last month in the U.S. as the first ever treatment for nonalcoholic steatohepatitis (NASH), a severe type of…
Girl with biliary atresia spotlighted in 2024 ALF Liver Life Walk
Five-year-old Sadie Sellers, who was born with biliary atresia, is the focus of a fundraising event designed to raise awareness of and funds for…
Elafibranor for PBC may become Genfit’s first approved molecule
Elafibranor, an oral molecule under regulatory review as a new second-line treatment for adults with primary biliary cholangitis (PBC), may become the first candidate…
Chiglitazar lowers MASH patients’ liver fat accumulation: Phase 2 trial
Chiglitazar (carfloglitazar), an oral medication approved to treat type 2 diabetes in China, led to significant reductions in liver fat accumulation among people with nonalcoholic…
